Skip to content
Back to search results

Willingness to Pay (WTP) in Health Economics

Introduced by
Carson & Louviere (stated preference/contingent valuation methods)
Year
1980s
Type
Method
Family
health valuation methodology
Font size

What does it do?

Willingness to pay (WTP) is an economic valuation method that elicits what individuals or society are willing to spend for a health benefit or to avoid a health risk.

Rooted in contingent valuation (Carson & Louviere, 1980s), WTP is used to monetize health outcomes for cost-benefit analysis and to infer implicit cost-effectiveness thresholds from actual healthcare spending patterns. Unlike revealed preference (observing actual spending behavior), WTP uses stated preferences—surveys asking respondents: 'How much would you pay for this health improvement?'

The intuition behind the method

Cost-benefit analysis requires putting a dollar value on health. A program improves health outcomes by 1,000 QALYs; what is that worth? Markets rarely reveal prices for 'a year of healthy life.' WTP surveys ask people directly: 'How much would you pay out-of-pocket to gain 1 QALY?' or 'What is the maximum fee you accept for a health risk?' Average responses provide a monetized valuation. Example: Survey 1,000 people: 'Would you pay $10,000 for a cervical cancer vaccine preventing lifetime infection risk of 5%?' If 70% say yes, $20,000 say yes, $30,000 say no, the implied WTP threshold is roughly $20,000. Aggregated across population (1 million women), vaccine program worth $20 billion in total WTP. This enables comparison with program cost: if vaccine costs $15 billion, net benefit = $5 billion (cost-benefit favorable). WTP is powerful but problematic: people have little experience valuing health (stated vs actual behavior differ); income constraints limit low-income populations' ability to pay (equity concern); and hypothetical scenarios may not elicit 'true' preferences.

History

Contingent valuation (CV) emerged in environmental economics (1960s–70s) to value ecosystem services (clean air, biodiversity) lacking markets. Carson & Mitchell (1989) applied CV to health (value of avoided respiratory symptoms). Boom in health WTP studies: 1990s–2000s, hundreds of health valuation surveys conducted. Criticism: Kahneman & Tversky (1979) highlighted biases (framing, hypothetical bias); studies showed WTP highly sensitive to question wording, which undermined confidence. Defenders argued WTP captures genuine preferences not revealed in behavior. Discrete choice experiments (DCE) emerged as alternative, arguably more realistic (respondents choose between constrained options, like real purchasing). By 2010s, most health WTP studies use DCE or hybrid methods. NICE (UK) in 2008 began revealing its implicit cost-effectiveness threshold (£20,000–£30,000/QALY) partly by looking at WTP patterns in society. Today, WTP is accepted tool but with caveats: used alongside revealed preference, adjusted for biases, and reported with uncertainty.

When to use it

When health benefit lacks market price or needs to be monetized for cost-benefit analysis. WTP is used for: (1) valuing non-market health outcomes (quality of life, life expectancy, risk reduction); (2) informing optimal pricing of health services; (3) estimating economic value of public health programs for budget justification; (4) revealing implicit societal threshold for health spending. Not appropriate for: price-regulated commodities (use market prices instead); acute life-saving interventions (ethical concerns with 'willingness to pay for life'); populations unable to afford even necessary care (income constraints make WTP responses meaningless).

Limitations and considerations

  • Hypothetical bias: respondents state WTP in surveys but behave differently when real money is at stake. Stated WTP typically 2–10× higher than revealed preference. Open questions: is survey WTP inflated, or is revealed behavior constrained by income/information?
  • Income constraint: low-income respondents state zero or minimal WTP for health improvements due to budget limits, not because they don't value health. WTP becomes regressive (rich value health more). Aggregate WTP may be biased toward wealthy.
  • Scope insensitivity: respondents sometimes state similar WTP for small vs large health improvements (should increase with magnitude). Suggests preferences are not well-formed for unfamiliar health scenarios.
  • Elicitation method matters: OE (open-ended) vs CE (closed-ended) vs DCE (discrete choice) yield different WTP; no clear consensus on 'best' method. Methodological choice influences results.
  • Context and framing effects: 'Would you pay for vaccination?' (gain frame) vs 'Would you accept payment to forgo vaccination?' (loss frame) yields different WTP due to loss aversion. Which is 'true' preference?

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Captures public/patient preferences directly: WTP reflects what people actually value, not clinician or economist assumptions about health importance.
  • Enables monetization of non-market goods: QALYs, DALYs, risk reduction can be valued in dollars, enabling cost-benefit analysis and cross-sector comparison.
  • Flexible and adaptable: can elicit WTP for specific attributes (e.g., vaccine efficacy vs side effect reduction) using discrete choice methods, enabling detailed valuation.
  • Informs pricing and policy: WTP surveys provide evidence on optimal price for health services and on acceptable health spending levels in society.

Applications

  • Pharmaceutical pricing: Company conducts WTP survey in target population; if mean WTP = $50,000/year and eligible population = 500,000, revenue potential = $25 billion. Price set to capture share of surplus without killing demand.
  • Public health program justification: Government evaluates HPV vaccination program; WTP survey shows mean WTP = $300/vaccine dose × 1 million adolescents = $300M total WTP. Program cost $100M; cost-benefit favorable, supports government funding.
  • Healthcare system threshold setting: NICE initially used £20,000/QALY threshold partly based on implicit WTP: analyzing healthcare spending revealed citizens accept interventions up to this amount. Setting official threshold requires WTP evidence.
  • Patient shared decision-making: Urologist and patient discuss prostate cancer screening options; WTP for early detection varies: some (high WTP) prefer aggressive screening; others (low WTP) prefer watchful waiting. WTP reveals patient values.
  • Equity impact assessment: WTP survey for contraception subsidy shows high-income women WTP $500/year; low-income women WTP $50/year. Gap illustrates inequality; policy considers income-subsidized access to equalize burden.

How it works

How it works

1

Step 1: Define the health state or intervention clearly. Example: 'A new cholesterol drug reduces your risk of heart attack by 30% over 10 years, with minor side effects (occasional headache, 5% risk). No other lifestyle changes.' Step 2: Choose elicitation method. (A) Open-ended (OE): 'What is the maximum you would pay annually for this drug?' Respondent states amount; captures true WTP but prone to anchoring bias and outliers. (B) Closed-ended (CE) / Dichotomous choice: Present a price, ask yes/no: 'Would you pay $500/year?' If yes, ask $750; if no, ask $250. Use binary search to converge on threshold. Reflects real purchasing decision (yes/no) but less precise than OE. (C) Discrete choice experiment (DCE): Present profiles of two drugs with different costs and attributes: 'Drug A: $600/year, 30% risk reduction, rare side effects' vs 'Drug B: $1,000/year, 40% risk reduction, no side effects. Which do you prefer?' Respondents choose; regression reveals implicit value of each attribute (WTP per 10% risk reduction, etc.). (D) Visual analog/Likert scales: Rate importance or preference; indirect valuation. Step 3: Sample: recruit representative sample (general population, patients with condition, healthcare workers). Online surveys quickest; in-person interviews allow clarification but costlier. Aim for 200–1,000 respondents (larger for subgroup analysis). Step 4: Pilot and validation: test survey for comprehension, bias, and realistic scenarios. Validate against actual market prices when possible (e.g., WTP for vaccination should align with actual price paid in other countries).

Formula
Design valuation scenario describing a health state, treatment outcome, or health service. Administer survey or interview to representative sample (general public, patients, healthcare providers). Elicit willingness to pay using open-ended questions ('What is the maximum you would pay?'), closed-ended/bidding ('Would you pay $X?'), discrete choice ('Choose between Option A at $X and Option B at $Y'), or ranking ('Rank these health scenarios by preference').
2

Raw data: respondents' stated amounts. Calculate: (1) Mean WTP = Σ(WTP_i) / n. (2) Median WTP = 50th percentile (more robust to outliers than mean). (3) Parametric modeling: assume WTP follows distribution (lognormal common in health) and estimate parameters. (4) Regression analysis: WTP = β0 + β1(age) + β2(income) + β3(disease_severity) + error. Identifies factors driving WTP (e.g., do wealthy respondents have higher WTP? Do sicker patients?). (5) Aggregation: if sample WTP = $500 per person annually, and eligible population = 1 million, total WTP valuation = $500M. Example: Cervical cancer vaccine survey, n=1,500 women. OE method: mean WTP = $2,300 (SD $1,800), median = $1,500. By age: 18–30 years: median $1,200; 31–50 years: median $2,000; >50 years: median $500 (declining risk reduces WTP). Regression: each additional infection risk percentage increases WTP by $45; side effect severity decreases WTP by $30/severity point. Robustness: test different elicitation methods (OE vs DCE) to see if WTP consistent.

Formula
Analyze responses: calculate mean/median WTP per respondent. Conduct econometric regression to identify factors associated with WTP (age, income, disease severity, risk aversion). Test for validity: compare hypothetical WTP to revealed preference benchmarks (actual prices paid, economic theory predictions).
3

Use WTP estimates in two ways: (1) Cost-Benefit Analysis: Total societal WTP for program = mean WTP × population × probability willing to adopt. Compare to program cost. If societal WTP ($500M) > program cost ($300M), program is cost-beneficial. (2) Implicit Threshold: National healthcare system's cost-effectiveness threshold (e.g., £20,000/QALY in UK) can be inferred from WTP. If NICE publicly funds interventions up to £20,000/QALY but not £30,000/QALY, this reveals implicit WTP. For new drug with uncertain cost-effectiveness, compare calculated ICER to revealed WTP threshold. WTP also informs pricing: pharmaceutical company may set price informed by WTP survey. If WTP = $30,000/year and estimated population = 100,000, revenue potential = $3 billion; company can optimize price/volume trade-off. Limitations: WTP surveys are hypothetical (real behavior often differs); income-constrained respondents state low WTP even for life-saving treatments (equity issue); WTP varies by framing ('Would you pay for vaccine?' vs 'Would you accept compensation to forgo vaccine?' typically yield different answers).

Formula
Use WTP estimates to value health outcomes in cost-benefit analysis or as implicit threshold in cost-effectiveness analysis. Example: if healthcare system implicit WTP threshold is £20,000/QALY (revealed from past reimbursement decisions), compare new drug ICER to this. If WTP survey shows patients willing to pay $100,000 for new cancer treatment, use to value QALYs gained in cost-benefit framework.

Common pitfalls

  • Ignoring hypothetical bias: using WTP estimates from surveys directly in cost-benefit analysis without adjustment for hypothetical inflation. Best practice: conduct 'cheap talk' (tell respondents their answers influence real policy) or real-money experiments (small incentivized payments) to improve accuracy.
  • Anchoring to arbitrary prices: if survey asks 'Would you pay $500?' first, then $1,000, responses anchor to initial value. Randomize order or use open-ended elicitation to avoid anchoring.
  • Aggregating across heterogeneous populations: if rich and poor have vastly different WTP, averaging is misleading. Report distributions, median, and stratified by income; acknowledge equity implications.
  • Confusing WTP with ability to pay: WTP is preference; ability to pay is income constraint. A low-income person may have high WTP (valuation) but low ability to pay (budget). Policy decisions should distinguish.
  • Failing to validate against market benchmarks: if WTP survey of pneumococcal vaccine yields $10,000 per dose, but actual market price is $200, survey is implausible. Validation against real prices (other countries, revealed preference) is essential.

Frequently asked questions

Why does willingness to pay differ from willingness to accept compensation?

Willingness to Pay (WTP) is the maximum you pay to gain a good; Willingness to Accept (WTA) is minimum payment you demand to forgo a good. Due to loss aversion, WTA > WTP (you demand more to give up something than you'd pay to acquire it). Example: smokers asked 'How much to quit smoking?' (WTP) might say $5,000/year; asked 'How much to start smoking?' (WTA) might say $50,000/year. This asymmetry is robust but complicates health valuation. Convention: use WTP for health improvements, WTA for health risks, but acknowledge gap.

How should WTP be adjusted for hypothetical bias?

Methods: (1) Cheap talk: tell respondents that survey results influence policy; this commitment device reduces hypothetical bias by ~25–50%. (2) Real-money experiments: conduct small incentivized trial (offer lottery, small real payment contingent on honest answer). (3) Calibration: if other studies show stated WTP is 3× actual, apply 3× discount factor. (4) Revealed preference: use actual market prices (co-payments, vaccine prices) as validation; if WTP much higher, discount WTP proportionally. Most rigorous: combination (cheap talk + real incentives + external validation).

Can WTP be used to compare across countries with different incomes?

Not directly. A US respondent (median income $60,000) might have WTP $10,000 for a vaccine; Nigerian respondent (median income $2,000) might have WTP $200—not because they value health differently, but due to income. For cross-country comparison: normalize WTP by income (e.g., % of annual income willing to pay) or use purchasing power parity (PPP) adjustments. Alternatively, use preference (DCE ranks, visual scales) rather than monetary WTP, which is less income-sensitive.

How large should WTP survey sample be?

Minimum: 200–300 respondents for point estimate of mean WTP and basic subgroup analysis (age, gender). Larger (500–1,000+) if: (1) population is very heterogeneous (mean may mask diverse preferences); (2) subgroup analysis planned (separate estimates for patient types); (3) interaction effects of interest (e.g., does income modify effect of disease severity on WTP?). Sample size also depends on precision desired (confidence interval width) and expected variability in WTP.

What is the difference between WTP and quality-adjusted life year (QALY) valuations?

WTP is monetary valuation of health derived from preferences ('What would you pay for this health state?'). QALY is a utility weight (0–1 scale) derived from preference elicitation (EQ-5D, TTO, VAS) ('How good is this health state?'). To convert: WTP can be used to infer implicit QALY value. If society WTP is $100,000 and a drug gains 5 QALYs, implicit value = $100,000 / 5 = $20,000/QALY (NICE-like threshold). Conversely, if WTP threshold is known, can assign cost-effectiveness threshold for QALYs.

Related methods

Sources

  1. Carson, R. T., & Louviere, J. J. (2011). A Common Nomenclature for Stated Choice Studies. In S. Hess & A. Daly (Eds.), Choice Modelling: The State of the Art and the State of Practice. Cheltenham: Edward Elgar.

    Open publication reference
    Copied.
  2. Grosse, S. D. (2008). Assessing Cost-Effectiveness in Healthcare: History of the $50,000-per-Life-Year Benchmark. Health Care Management Science, 11(2), 176-182.

    Open publication reference
    Copied.
  3. Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the Economic Evaluation of Health Care Programmes (4th ed.). Oxford: Oxford University Press.

    Open publication reference
    Copied.